On March 19, 2026, Acrivon Therapeutics, Inc. announced its financial results for the year ending December 31, 2025, and detailed updates on its drug study, ACR-368, which shows promise in treating endometrial cancer.
AI Assistant
ACRIVON THERAPEUTICS INC
2026
8 K
Find Answers
Ask about any part of the document to get insights, explanations, or key details.